Cargando…
Astragaloside IV Blunts Epithelial–Mesenchymal Transition and G2/M Arrest to Alleviate Renal Fibrosis via Regulating ALDH2-Mediated Autophagy
Previous studies show that astragaloside IV (ASIV) has anti-renal fibrosis effects. However, its mechanism remains elusive. In this study, we investigated the anti-fibrosis mechanisms of ASIV on chronic kidney disease (CKD) in vivo and in vitro. A CKD model was induced in rats with adenine (200 mg/k...
Autores principales: | Li, Dong, Liu, Yuzhe, Zhan, Quancao, Zeng, Yan, Peng, Ze, He, Qifeng, Tan, Qi, Cao, Wenfu, Wang, Shang, Wang, Jianwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340704/ https://www.ncbi.nlm.nih.gov/pubmed/37443810 http://dx.doi.org/10.3390/cells12131777 |
Ejemplares similares
-
Astragaloside IV alleviates heart failure by modulating Nrf-2
por: Feng, Wenxiao, et al.
Publicado: (2022) -
Astragaloside IV alleviates liver injury in type 2 diabetes due to promotion of AMPK/mTOR-mediated autophagy
por: Zhu, Yunfeng, et al.
Publicado: (2021) -
Astragaloside IV Attenuates the Myocardial Injury Caused by Adriamycin by Inhibiting Autophagy
por: Luo, Li-Fei, et al.
Publicado: (2021) -
Astragaloside IV alleviates myocardial damage induced by type 2 diabetes via improving energy metabolism
por: Zhang, Zhen, et al.
Publicado: (2019) -
Astragaloside IV alleviates placental oxidative stress and inflammation in GDM mice
por: Zhou, Ling, et al.
Publicado: (2020)